Curaleaf Laboratories launches UK medical cannabis suppositories, first of format

Curaleaf Laboratories becomes first UK manufacturer of medical cannabis suppositories, adding alternative delivery method.

FILE — retail · My 420 Tours / CC BY-SA 4.0

Curaleaf Laboratories has begun manufacturing medical cannabis suppositories in the UK, marking the first domestic production of that delivery format, according to MMJDaily. The move comes as the UK medical cannabis market expands, with projections suggesting patient numbers could exceed 140,000 by 2026.

Suppositories represent a less-common dosage form in cannabis therapeutics but may appeal to patients seeking alternatives to smoking, vaping, or oral ingestion. The timing aligns with broader European market consolidation—recent months have seen multiple cannabis operators either entering UK distribution agreements or expanding regional footprints through partnerships.

Key to watch: whether Curaleaf's suppository introduction prompts competing manufacturers to develop similar formulations, or whether regulatory or supply constraints limit adoption among the projected patient population.